Metastatic disease

Clinical trials

Clinical trials

Access to clinical trials

All patients with a diagnosis of recurrent or metastatic bladder cancer, and particularly those whose prior chemotherapy has been unsuccessful, should be considered for centres where clinical trials are available.

A limited but increasing number of studies are available in various settings for patients who have never had chemotherapy as well as pre-treated patients. In addition, the recent experimental use of drugs called ‘immune checkpoint inhibitors’ in advanced bladder cancer appears effective in a subset of patients with this disease.

Access to clinical trials should be the first option to discuss with your physician. The therapeutic decision is made after reviewing thorough information on the pros and cons of each option and depending on the individual patient and disease characteristics.

error: You are not allowed to copy content without permission. Please contact: e.robijn@uroweb.org